Loading...
Loading...
NEW YORK, NY · CIK 0001263508
New positions
7
Added to
18
Trimmed
6
Exited
13
Sectors derived from SEC SIC codes, value-weighted. Positions without a resolvable ticker are shown as Unclassified.
Baker Bros' $17.4B biotech book stays anchored by INCY (16.6%) and ONC (15%). The quarter was housekeeping: INSM added 13%, ELVN +234% from a small base, against deep cuts to IMCR (−68%) and BNTX (−68%). Concentrated, slow-moving, and highly binary — position sizes here reflect clinical conviction, not momentum.
Generated quarterly from the filing data itself — holdings, changes, sector mix and clone-performance rank. Not investment advice.
Source: SEC 13F-HR filing filed on 2026-05-15 ·View on SEC.gov →
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | INCYIncyte Corporation | $2.89B | 16.62% | +0.0% |
| 2 | ONCBeOne Medicines Ltd. | $2.61B | 15.00% | - |
| 3 | INSMInsmed Incorporated | $1.21B | 6.97% | +12.6% |
| 4 | MDGLMadrigal Pharmaceuticals, Inc. | $1.12B | 6.44% | - |
| 5 | ACADACADIA Pharmaceuticals Inc. | $954.88M | 5.48% | - |
| 6 | RVMDRevolution Medicines, Inc. | $929.26M | 5.34% | +1.1% |
| 7 | CELCCelcuity Inc. | $903.51M | 5.19% | - |
| 8 | KODKodiak Sciences Inc. | $759.32M | 4.36% | - |
| 9 | KYMRKymera Therapeutics, Inc. | $721.06M | 4.14% | - |
| 10 | SMMTSummit Therapeutics Inc. | $689.97M | 3.96% | - |
| Stock | Value | Shares |
|---|---|---|
| MIRMMirum Pharmaceuticals, Inc. | $41.20M | 445,975 |
| EVMNEvommune, Inc. | $19.48M | 847,390 |
| AKTSAktis Oncology, Inc. | $17.82M | 996,351 |
| GENBGenerate Biomedicines, Inc. | $17.80M | 1,423,602 |
| CMPSCOMPASS Pathways plc | $12.97M | 2,344,720 |
| EIKNEikon Therapeutics, Inc. | $5.88M | 555,555 |
| VSTMVerastem, Inc. | $3.10M | 584,757 |
As of Q1 2026, BAKER BROS. ADVISORS LP reported a portfolio value of $17.42B across 84 positions in their 13F filing.
BAKER BROS. ADVISORS LP's largest holding is INCY with a position worth $2.89B. Their top holdings include INCY, ONC, INSM, MDGL, ACAD.
In Q1 2026, BAKER BROS. ADVISORS LP made the following changes to their portfolio: 7 new positions, 13 positions sold out, 18 positions increased, 6 positions reduced.
BAKER BROS. ADVISORS LP files quarterly 13F reports with the SEC, disclosing their long positions in U.S. equities. These filings are due within 45 days of the quarter end and provide transparency into their investment strategy and portfolio allocation.
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.